In vivo delivery of nucleic acids via glycopolymer vehicles affords therapeutic infarct size reduction in vivo

Molecular Therapy

Volumn 20, Issue 3, 2012, Pages 601-608

  Tranter, Michael ^a   Liu, Yemin ^b   He, Suiwen ^a   Gulick, James ^c   Ren, Xiaoping ^a   Robbins, Jeffrey ^c   Jones, W Keith ^a   Reineke, Theresa M ^a,d  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^b VIRGINIA POLYTECHNIC INSTITUTE AND STATE UNIVERSITY   (United States)

^c CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^d UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOOXYGENASE 2; DEOXYRIBONUCLEASE I; DOUBLE STRANDED DNA; GLYCOPOLYMER; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; NANOPARTICLE; NUCLEIC ACID; OLIGONUCLEOTIDE; POLYGLYCOAMIDOAMINE; POLYMER; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFICACY; GEL ELECTROPHORESIS; GEL MOBILITY SHIFT ASSAY; GENE EXPRESSION; HEART INFARCTION; HEART INFARCTION SIZE; HEART MUSCLE; HEART MUSCLE CELL; HEART MUSCLE ISCHEMIA; IN VIVO STUDY; INNATE IMMUNITY; LIGHT SCATTERING; MOUSE; NANOMEDICINE; NEWBORN; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; PHENOTYPE; PROTEIN DNA BINDING; RAT; REPERFUSION INJURY; TRANSMISSION ELECTRON MICROSCOPY;

ANIMALIA; MUS MUSCULUS;

EID: 84857793580     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2011.267     Document Type: Article

References (36)

1. Davis, ME (2002). Non-viral gene delivery systems. Curr Opin Biotechnol 13: 128-131. (Pubitemid 34310371)
2. Luo, D and Saltzman, WM (2000). Synthetic DNA delivery systems. Nat Biotechnol 18: 33-37. (Pubitemid 30041168)
3. Han, S, Mahato, RI, Sung, YK and Kim, SW (2000). Development of biomaterials for gene therapy. Mol Ther 2: 302-317.
4. Schaffer, DV, Koerber, JT and Lim, KI (2008). Molecular engineering of viral gene delivery vehicles. Annu Rev Biomed Eng 10: 169-194.
5. De Smedt, SC, Demeester, J and Hennink, WE (2000). Cationic polymer based gene delivery systems. Pharm Res 17: 113-126. (Pubitemid 30158358)
6. Davis, ME, Pun, SH, Bellocq, NC, Reineke, TM, Popielarski, SR, Mishra, S et al. (2004). Self-assembling nucleic acid delivery vehicles via linear, water-soluble, cyclodextrincontaining polymers. Curr Med Chem 11: 179-197. (Pubitemid 38128844)
7. Hashida, M, Kawakami, S and Yamashita, F (2005). Lipid carrier systems for targeted drug and gene delivery. Chem Pharm Bull 53: 871-880. (Pubitemid 41327672)
8. Mary Ann Liebert, Inc. (2002). Assessment of adenoviral vector safety and toxicity: report of the National Institutes of Health Recombinant DNA Advisory Committee. Hum Gene Ther 13: 3-13.
9. Hacein-Bey-Abina, S, Von Kalle, C, Schmidt, M, McCormack, MP, Wulffraat, N, Leboulch, P et al. (2003). LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science 302: 415-419. (Pubitemid 37296260)
10. McBain, SC, Yiu, HH and Dobson, J (2008). Magnetic nanoparticles for gene and drug delivery. Int J Nanomedicine 3: 169-180. (Pubitemid 352037850)
11. Gao, X, Kim, KS and Liu, D (2007). Nonviral gene delivery: what we know and what is next. AAPS J 9: E92-104.
12. Liu, Y and Reineke, TM (2005). Hydroxyl stereochemistry and amine number within poly(glycoamidoamine)s affect intracellular DNA delivery. J Am Chem Soc 127: 3004-3015. (Pubitemid 40349880)
13. Liu, Y, Wenning, L, Lynch, M and Reineke, TM (2004). New poly(dglucaramidoamine) s induce DNA nanoparticle formation and efficient gene delivery into mammalian cells. J Am Chem Soc 126: 7422-7423. (Pubitemid 38781459)
14. Liu, Y and Reineke, TM (2007). Poly(glycoamidoamine)s for gene delivery. structural effects on cellular internalization, buffering capacity, and gene expression. Bioconjug Chem 18: 19-30. (Pubitemid 46145991)
15. Liu, Y and Reineke, TM (2006). Poly(glycoamidoamine)s for gene delivery: stability of polyplexes and efficacy with cardiomyoblast cells. Bioconjug Chem 17: 101-108. (Pubitemid 43157590)
16. Kumar, A, Takada, Y, Boriek, AM and Aggarwal, BB (2004). Nuclear factor-kappaB: its role in health and disease. J Mol Med 82: 434-448. (Pubitemid 39044283)
17. Jones, WK, Brown, M, Ren, X, He, S and McGuinness, M (2003). NF-kappaB as an integrator of diverse signaling pathways: the heart of myocardial signaling? Cardiovasc Toxicol 3: 229-254.
18. Li, HL, Zhuo, ML, Wang, D, Wang, AB, Cai, H, Sun, LH et al. (2007). Targeted cardiac overexpression of A20 improves left ventricular performance and reduces compensatory hypertrophy after myocardial infarction. Circulation 115: 1885-1894. (Pubitemid 46598902)
19. Gupta, S, Young, D, Maitra, RK, Gupta, A, Popovic, ZB, Yong, SL et al. (2008). Prevention of cardiac hypertrophy and heart failure by silencing of NF-kappaB. J Mol Biol 375: 637-649.
20. Valen, G, Yan, ZQ and Hansson, GK (2001). Nuclear factor kappa-B and the heart. J Am Coll Cardiol 38: 307-314. (Pubitemid 32721754)
21. Kubota, T, Miyagishima, M, Frye, CS, Alber, SM, Bounoutas, GS, Kadokami, T et al. (2001). Overexpression of tumor necrosis factor-alpha activates both anti-and pro-apoptotic pathways in the myocardium. J Mol Cell Cardiol 33: 1331-1344. (Pubitemid 32613425)
22. Brown, M, McGuinness, M, Wright, T, Ren, X, Wang, Y, Boivin, GP et al. (2005). Cardiac-specific blockade of NF-kappaB in cardiac pathophysiology: differences between acute and chronic stimuli in vivo. Am J Physiol Heart Circ Physiol 289: H466-H476. (Pubitemid 40934134)
23. Zingarelli, B, Sheehan, M and Wong, HR (2003). Nuclear factor-kappaB as a therapeutic target in critical care medicine. Crit Care Med 31(1 Suppl): S105-S111. (Pubitemid 36143484)
24. Kerkel̈ R, Grazette, L, Yacobi, R, Iliescu, C, Patten, R, Beahm, C et al. (2006). Cardiotoxicity of the cancer therapeutic agent imatinib mesylate. Nat Med 12: 908-916.
25. Liu, SF, Ye, X and Malik, AB (1999). Inhibition of NF-kappaB activation by pyrrolidine dithiocarbamate prevents In vivo expression of proinflammatory genes. Circulation 100: 1330-1337. (Pubitemid 29440127)
26. Ren, X, Wang, Y and Jones, WK (2004). TNF-alpha is required for late ischemic preconditioning but not for remote preconditioning of trauma. J Surg Res 121: 120-129. (Pubitemid 39094105)
27. Moss, NC, Stansfield, WE, Willis, MS, Tang, RH and Selzman, CH (2007). IKKbeta inhibition attenuates myocardial injury and dysfunction following acute ischemiareperfusion injury. Am J Physiol Heart Circ Physiol 293: H2248-H2253. (Pubitemid 47605868)
28. Morishita, R, Sugimoto, T, Aoki, M, Kida, I, Tomita, N, Moriguchi, A et al. (1997). In vivo transfection of cis element "decoy" against nuclear factor-kappaB binding site prevents myocardial infarction. Nat Med 3: 894-899. (Pubitemid 27353450)
29. Lam, AP and Dean, DA (2010). Progress and prospects: nuclear import of nonviral vectors. Gene Ther 17: 439-447.
30. McLendon, PM, Buckwalter, DJ, Davis, EM and Reineke, TM (2010). Interaction of Poly(glycoamidoamine) DNA Delivery Vehicles with Cell-Surface Glycosaminoglycans Leads to Polyplex Internalization in a Manner Not Solely Dependent on Charge. Mol Pharm 7: 1757-1768.
31. McLendon, PM, Fichter, KM and Reineke, TM (2010). Poly(glycoamidoamine) vehicles promote pDNA uptake through multiple routes and efficient gene expression via caveolae-mediated endocytosis. Mol Pharm 7: 738-750.
32. Sakurai, H, Kawabata, K, Sakurai, F, Nakagawa, S and Mizuguchi, H (2008). Innate immune response induced by gene delivery vectors. Int J Pharm 354: 9-15. (Pubitemid 351400322)
33. Liu, Y and Reineke, TM (2010). Degradation of poly(glycoamidoamine) DNA delivery vehicles: polyamide hydrolysis at physiological conditions promotes DNA release. Biomacromolecules 11: 316-325.
34. Ditto, AJ, Shah, PN and Yun, YH (2009). Non-viral gene delivery using nanoparticles. Expert Opin Drug Deliv 6: 1149-1160.
35. Fishbein, MC, Meerbaum, S, Rit, J, Lando, U, Kanmatsuse, K, Mercier, JC et al. (1981). Early phase acute myocardial infarct size quantification: validation of the triphenyl tetrazolium chloride tissue enzyme staining technique. Am Heart J 101: 593-600. (Pubitemid 11120523)
36. Livak, KJ and Schmittgen, TD (2001). Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25: 402-408. (Pubitemid 34164012)